- Sona Nanotech (CSE:SONA) has revealed additional results from the triple-negative breast cancer murine model portion of its research study at Dalhousie University in Halifax, Nova Scotia
- The study confirms previously reported tumor volume reduction as a result of a tumor-specific systemic immune response
- Data also relates to follow-up biomarker analysis performed on a cohort of animals that showed a significant effect in shrinking treated and untreated tumors
- Shares of Sona Nanotech are down 4.88 per cent to C$0.39 as of 10:01 am ET
Sona Nanotech (CSE:SONA) has revealed additional results from the triple-negative breast cancer murine model portion of its research study at Dalhousie University in Halifax, Nova Scotia.
The company stated in a news release that the study confirms previously reported tumor volume reduction as a result of a tumour-specific systemic immune response.
Data relates to the follow-up biomarker analysis done on a previous cohort of animals that showed a significant effect in treated and untreated tumors in animals bearing multiple tumors after being treated with the company’s targeted hyperthermia therapy (THT) and interleukin-2 (IL-2) immunotherapy.
“We are very pleased to see the study data confirm that Sona’s THT, when combined with a standard immunotherapy agent to treat a single tumor, creates a response consistent with an abscopal effect by modulating the entire immune system, beneficially impacting distant, untreated tumors in this triple-negative breast cancer mouse model,” David Regan, CEO of Sona Nanotech, said in a statement.
Thanks to the results, Sona Nanotech can now move forward with initiating safety, biocompatibility and efficacy studies ahead of being considered for first-in-human studies.
The study included 26 mice bearing multiple triple-negative breast cancer tumors. This included a control group of six, with seven given IL-2 only, seven given THT only and the other cohort that was administered the combination of the generation of hyperthermia followed by intratumoral injections with IL-2.
Sona Nanotech stated the next step will be assessing the therapy’s ability to generate similar results in melanoma and colorectal cancer mouse models and determine the extent to which it can eliminate untreated distant tumors for these cancers.
With its headquarters out of Halifax, Nova Scotia, Sona Nanotech is a life sciences company focused on developing Targeted Hyperthermia, a photothermal cancer therapy that uses therapeutic heat to treat solid cancer tumors.
Shares of Sona Nanotech Inc. (CSE:SONA) are down 4.88 per cent to C$0.39 as of 10:01 am ET.
Join the discussion: Find out what everybody’s saying about this stock on the Sona Nanotech Inc. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
